Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ABEO with free AI briefings, catalyst countdowns, and dilution alerts.

ABEO · Abeona Therapeutics Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$134.9M Cash on Hand
31.4mo Cash Runway
31.7% Short Interest
$15.56 Analyst Target (8)
Follow ABEO by email Get an email when ABEO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ABEO, unsubscribe in one click. Privacy

📣 What ABEO Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Non-conforming pz-cel surgical application to… Epidermolysis Bullosa (EB) Phase 4 · NCT07717736 Not yet recruiting
Pz-cel surgical application to DEB wounds Epidermolysis Bullosa (EB) Phase 4 · NCT07717736 Not yet recruiting
EB-101 Epidermolysis Bullosa Phase 3 · NCT04227106 Completed
EB-101 Surgical application of RDEB wounds Epidermolysis Bullosa Phase 3 · NCT05725018 Active not recruiting
MSI-78 Diabetic Foot Ulcers Phase 3 · NCT00563394 Completed
Optimized Prophylactic IM Therapy MPS IIIA Phase 2/3 · NCT02716246 Recruiting
Prophylactic Immunomodulatory (IM) Therapy MPS IIIA Phase 2/3 · NCT02716246 Recruiting
Rebisufligene Etisparvovec MPS IIIA Phase 2/3 · NCT02716246 Recruiting
ABO-102 MPS IIIA Phase 1/2 · NCT04088734 Terminated
Econazole Onychomycosis Phase 2 · NCT00385502 Completed
LZRSE-Col7A1 Engineered Autologous Epidermal… Epidermolysis Bullosa Dystrophica Phase 1/2 · NCT01263379 Completed
rAAV9.CMV.hNAGLU Mucopolysaccharidosis Type 3 B Phase 1/2 · NCT03315182 Terminated
ABO-101 Mucopolysaccharidosis III-B N/A · NCT04655911 Terminated

Also used in these trials (approved or third-party drugs, not ABEO's own candidates): Adjuvant IM Therapy, Ofloxacin Otic.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ABEO holds $134.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $12.9M/quarter from operations, an estimated runway of 31.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 15 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ABEO files for a raise →

👥 Who Owns ABEO

Insiders 6.2% Other 5%+ holders 36.5% Institutions (158 holders) 57.3% Public and other holders 0%
HolderTypeShares% of sharesAs of
Nantahala Capital Management, LLC Institution (13G, 5%+) 5,775,350 10.11% 2026-03-31
Funicular Funds, LP 5%+ holder (13G) 5,101,883 8.93% 2026-09-30
TPG GP A, LLC 5%+ holder (13G) 4,761,050 8.33% 2026-11-06
Daniel Kaufman 5%+ holder (13G) 4,159,099 7.28% 2026-09-30
James Russell Revocable Trust 5%+ holder (13D) 3,479,963 6.09% 2026-10-15
Blackrock Inc. Institution (13F) 3,376,695 5.91% 2026-09-30
Rubric Capital Management LP Institution (13G, 5%+) 3,339,707 5.84% 2026-09-30
NANTAHALA CAPITAL PARTNERS LIMITED PARTN 5%+ holder (13G) 3,333,757 5.83% 2026-03-31
Orin Hirschman Institution (13G, 5%+) 3,100,000 5.42% 2026-03-31
AIGH Capital Management LLC Institution (13F) 2,900,000 5.07% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 2,137,768 3.74% 2026-09-30
J. Goldman & Co., L.P. Institution (13F) 1,517,152 2.65% 2026-09-30

Share count 57,146,840 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-13
filed 2026-11-16
Charles Faith L.
Purchase (P) 15,000 $2.29 191,407
2026-09-29
filed 2026-09-29
O'Malley Brendan M.
Sale (S) 6,727 $5.16 421,226
2026-09-29
filed 2026-09-29
Vazzano Joseph Walter
Sale (S) 9,191 $5.16 482,888
2026-09-29
filed 2026-09-29
Seshadri Vishwas
Sale (S) 19,608 $5.16 1,286,500
2026-09-29
filed 2026-09-29
Vasanthavada Madhav
Sale (S) 4,902 $5.16 285,721

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full ABEO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ABEO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.